ライフサイエンスコーパス: primary aldosteronism

1 ists are the recommended medical therapy for primary aldosteronism.

2 ble way to correctly diagnose the subtype of primary aldosteronism.

3 ng from Cav1.3 hyperactivity, in particular, primary aldosteronism.

4 tension including obstructive sleep apnea or primary aldosteronism.

5 unction Ca(2+) channel mutations in APAs and primary aldosteronism.

6 o renin ratio is a useful screening tool for primary aldosteronism.

7 nsion often persists after adrenalectomy for primary aldosteronism.

8 xpanded extracellular fluid volume, e.g., in primary aldosteronism.

9 y 6 hours for 4 days) to diagnose or exclude primary aldosteronism.

10 nd follow-up of adrenalectomy for unilateral primary aldosteronism.

11 Patients with primary aldosteronism also had higher adjusted risks for

12 nd follow-up of adrenalectomy for unilateral primary aldosteronism and apply these criteria to an int

13 Classical primary aldosteronism and lesser degrees of aldosterone

14 Until the true prevalence of primary aldosteronism and monogenic forms of mineralocor

15 a previously undescribed syndrome featuring primary aldosteronism and neuromuscular abnormalities.

16 ociations between resistant hypertension and primary aldosteronism and with obstructive sleep apnea.

17 a detailed insight in the genetic causes of primary aldosteronism, and mineralocorticoid receptor bl

18 100 patients who underwent adrenalectomy for primary aldosteronism at one tertiary medical center and

19 ssment of patients diagnosed with unilateral primary aldosteronism by adrenal venous sampling who had

20 unrelated subjects with hypertension due to primary aldosteronism by age 10.

21 Primary aldosteronism comprises subtypes that need diffe

22 f mineralocorticoid hypertension is probably primary aldosteronism; controlled posture studies to mea

23 s occur in a handful of conditions including primary aldosteronism, distal renal tubular acidosis, Li

24 of radiofrequency (RF) ablation in treating primary aldosteronism due to aldosterone-producing adeno

25 We present an interesting case of primary aldosteronism in which planar scintigraphy and S

26 Primary aldosteronism is a potentially curable cause of

27 current practice of MR antagonist therapy in primary aldosteronism is associated with significantly h

28 Primary aldosteronism is common among patients with resi

29 tion of hypertension after adrenalectomy for primary aldosteronism is independently associated with a

30 Primary aldosteronism is recognized as a severe form of

31 Primary aldosteronism is the most common curable cause o

32 Although unilateral primary aldosteronism is the most common surgically corr

33 in members of four kindreds with early onset primary aldosteronism of unknown cause.

34 ovascular events was higher in patients with primary aldosteronism on MR antagonists than in patients

35 pertensive population the true prevalence of primary aldosteronism (PA) and its main subtypes, aldost

36 Primary aldosteronism (PA) causes excess left ventricula

37 xcess aldosterone secretion in patients with primary aldosteronism (PA) impairs their cardiovascular

38 Primary aldosteronism (PA) is a common and underdiagnose

39 Primary aldosteronism (PA) is common and associates with

40 Primary aldosteronism (PA) is the most common cause of s

41 Adrenocortical hormone excess, due to primary aldosteronism (PA) or hypercortisolemia, causes

42 pharmacological treatments on outcomes among primary aldosteronism (PA) patients.

43 Primary aldosteronism (PA) represents the most common ca

44 means to localize aldosterone production in primary aldosteronism (PA).

45 clinically relevant spectrum of subclinical primary aldosteronism (renin-independent aldosteronism)

46 Screening for primary aldosteronism should nonetheless be done in ever

47 The Primary Aldosteronism Surgical Outcome (PASO) study was

48 We identified 602 eligible patients with primary aldosteronism treated with MR antagonists and 41

49 ident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compar

50 We identified patients with primary aldosteronism using International Classification

51 Primary aldosteronism was confirmed by using the oral so

52 At 3-month follow-up, primary aldosteronism was resolved in 33 (92%) patients,

53 y clinical study of 677 participants without primary aldosteronism, who were studied on both high and

54 s and mortality was limited to patients with primary aldosteronism whose renin activity remained supp

55 ations for the diagnosis and pathogenesis of primary aldosteronism with and without adrenal hyperplas

56 iscovery that Cav1.3 gain-of-function causes primary aldosteronism with seizures, neurologic abnormal